{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:01:12Z","timestamp":1790114472827,"version":"4.0.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Autosomal Dominant Hypocalcemia type 1 (ADH1), caused by gain-of-function variants in the calcium-sensing receptor (CASR), is characterized by a variable degree of hypocalcemia and hypercalciuria with inappropriately low PTH. The clinical spectrum is broad, ranging from being asymptomatic to presenting with severe clinical features of hypocalcemia and end-organ damage such as nephrolithiasis and intracerebral calcifications. Although the underlying pathophysiology is different, ADH1 patients are often managed as patients with \u2018classical\u2019 primary hypoparathyroidism, possibly leading to (exacerbation of) hypercalciuria. New treatments such as PTH analogues and calcilytics directly targeting the CASR are in the pipeline. Specific clinical guidance for treatment and monitoring of ADH1 patients is lacking. The purpose of this study is to provide a literature review on management of ADH1, including new therapies, and to formulate practice recommendations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We searched for articles and ongoing clinical trials regarding management of ADH1.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Forty articles were included. First we review the conventional treatment of ADH1, focusing on active vitamin D, calcium supplements, thiazide diuretics, phosphorus binders and dietary recommendations. In a second part we give an overview of studies with emerging treatments in ADH1: PTH analogues (PTH1-34, rhPTH1-84, TransCon PTH and others) and calcilytics (preclinical studies and clinical trials). In a third part we discuss literature findings regarding monitoring of ADH1 patients. Finally, we formulate clinical practice recommendations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We provide an overview of conventional and new treatments for ADH1 patients. Based on these data, we propose practical recommendations to assist clinicians in the management of ADH1 patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s40618-024-02496-y","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T07:28:37Z","timestamp":1732778917000},"page":"831-844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Management of autosomal dominant hypocalcemia type 1: Literature review and clinical practice recommendations"],"prefix":"10.1007","volume":"48","author":[{"given":"Thomas","family":"De Coster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6050-6677","authenticated-orcid":false,"given":"Karel","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0734-5154","authenticated-orcid":false,"given":"Jeroen","family":"Breckpot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4153-4757","authenticated-orcid":false,"given":"Brigitte","family":"Decallonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"2496_CR1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/J.AJHG.2020.04.006","volume":"106","author":"R Dershem","year":"2020","unstructured":"Dershem R, Gorvin CM, Metpally RPR et al (2020) Familial hypocalciuric hypercalcemia type 1 and autosomal-Dominant Hypocalcemia Type 1: prevalence in a large Healthcare Population. Am J Hum Genet 106:734\u2013747. https:\/\/doi.org\/10.1016\/J.AJHG.2020.04.006","journal-title":"Am J Hum Genet"},{"key":"2496_CR2","doi-asserted-by":"publisher","unstructured":"Roszko KL, Bi RD, Mannstadt M (2016) Autosomal Dominant Hypocalcemia (Hypoparathyroidism) types 1 and 2. https:\/\/doi.org\/10.3389\/FPHYS.2016.00458. Front Physiol 7:","DOI":"10.3389\/FPHYS.2016.00458"},{"key":"2496_CR3","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/JBMR.4659","volume":"37","author":"KL Roszko","year":"2022","unstructured":"Roszko KL, Stapleton Smith LM, Sridhar AV et al (2022) Autosomal Dominant Hypocalcemia Type 1: a systematic review. J Bone Min Res 37:1926\u20131935. https:\/\/doi.org\/10.1002\/JBMR.4659","journal-title":"J Bone Min Res"},{"key":"2496_CR4","unstructured":"A new mutation in the calcium-sensing receptor gene causing hypocalcaemia: case report of a father and two sons - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/28741586\/. Accessed 10 Apr 2022"},{"key":"2496_CR5","doi-asserted-by":"publisher","unstructured":"Kinoshita Y, Hori M, Taguchi M et al (2014) Functional activities of mutant calcium-sensing receptors determine clinical presentations in patients with autosomal dominant hypocalcemia. J Clin Endocrinol Metab 99. https:\/\/doi.org\/10.1210\/JC.2013-3430","DOI":"10.1210\/JC.2013-3430"},{"key":"2496_CR6","doi-asserted-by":"publisher","unstructured":"van Megen WH, Tan RSG, Alexander RT, Dimke H (2022) Differential parathyroid and kidney Ca2+-sensing receptor activation in autosomal dominant hypocalcemia 1. https:\/\/doi.org\/10.1016\/J.EBIOM.2022.103947. EBioMedicine 78:","DOI":"10.1016\/J.EBIOM.2022.103947"},{"key":"2496_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/S00223-015-0052-Z","volume":"98","author":"EF Nemeth","year":"2016","unstructured":"Nemeth EF, Goodman WG (2016) Calcimimetic and calcilytic drugs: feats, flops, and futures. Calcif Tissue Int 98:341\u2013358. https:\/\/doi.org\/10.1007\/S00223-015-0052-Z","journal-title":"Calcif Tissue Int"},{"key":"2496_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/S41574-018-0115-0","volume":"15","author":"FM Hannan","year":"2018","unstructured":"Hannan FM, Kallay E, Chang W et al (2018) The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat Rev Endocrinol 15:33\u201351. https:\/\/doi.org\/10.1038\/S41574-018-0115-0","journal-title":"Nat Rev Endocrinol"},{"key":"2496_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/J.BEEM.2013.02.006","volume":"27","author":"EM Brown","year":"2013","unstructured":"Brown EM (2013) Role of the calcium-sensing receptor in extracellular calcium homeostasis. Best Pract Res Clin Endocrinol Metab 27:333\u2013343. https:\/\/doi.org\/10.1016\/J.BEEM.2013.02.006","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2496_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/J.ECL.2021.07.005","volume":"50","author":"N Matikainen","year":"2021","unstructured":"Matikainen N, Pekkarinen T, Ryh\u00e4nen EM, Schalin-J\u00e4ntti C (2021) Physiology of Calcium Homeostasis: an overview. Endocrinol Metab Clin North Am 50:575\u2013590. https:\/\/doi.org\/10.1016\/J.ECL.2021.07.005","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2496_CR11","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/HMG\/DDS105","volume":"21","author":"FM Hannan","year":"2012","unstructured":"Hannan FM, Nesbit MA, Zhang C et al (2012) Identification of 70 calcium-sensing receptor mutations in hyper- and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites. Hum Mol Genet 21:2768\u20132778. https:\/\/doi.org\/10.1093\/HMG\/DDS105","journal-title":"Hum Mol Genet"},{"key":"2496_CR12","doi-asserted-by":"publisher","unstructured":"Hannan FM, Gorvin CM, Babinsky VN et al (2020) Calcilytic NPSP795 increases plasma calcium and PTH in an autosomal Dominant Hypocalcemia Type 1 mouse model. https:\/\/doi.org\/10.1002\/JBM4.10402. JBMR Plus 4:","DOI":"10.1002\/JBM4.10402"},{"key":"2496_CR13","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JME-19-0104","volume":"63","author":"CM Gorvin","year":"2019","unstructured":"Gorvin CM (2019) Molecular and clinical insights from studies of calcium-sensing receptor mutations. J Mol Endocrinol 63:R1\u2013R16. https:\/\/doi.org\/10.1530\/JME-19-0104","journal-title":"J Mol Endocrinol"},{"key":"2496_CR14","doi-asserted-by":"publisher","unstructured":"Khan AA, Bilezikian JP, Brandi ML et al (2022) Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop. J Bone Miner Res. https:\/\/doi.org\/10.1002\/JBMR.4691","DOI":"10.1002\/JBMR.4691"},{"key":"2496_CR15","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1097\/01.ASN.0000025781.16723.68","volume":"13","author":"R Vargas-Poussou","year":"2002","unstructured":"Vargas-Poussou R, Huang C, Hulin P et al (2002) Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a bartter-like syndrome. J Am Soc Nephrol 13:2259\u20132266. https:\/\/doi.org\/10.1097\/01.ASN.0000025781.16723.68","journal-title":"J Am Soc Nephrol"},{"key":"2496_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/J.BERH.2007.11.006","volume":"22","author":"OI Egbuna","year":"2008","unstructured":"Egbuna OI, Brown EM (2008) Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract Res Clin Rheumatol 22:129\u2013148. https:\/\/doi.org\/10.1016\/J.BERH.2007.11.006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2496_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/S12519-020-00370-4","volume":"17","author":"FCC Mrad","year":"2021","unstructured":"Mrad FCC, Soares SBM, de Menezes Silva LAW et al (2021) Bartter\u2019s syndrome: clinical findings, genetic causes and therapeutic approach. World J Pediatr 17:31\u201339. https:\/\/doi.org\/10.1007\/S12519-020-00370-4","journal-title":"World J Pediatr"},{"key":"2496_CR18","doi-asserted-by":"publisher","unstructured":"Mannstadt M, Bilezikian JP, Thakker RV et al (2017) Hypoparathyroidism. Nat Rev Dis Primers 3. https:\/\/doi.org\/10.1038\/NRDP.2017.55","DOI":"10.1038\/NRDP.2017.55"},{"key":"2496_CR19","doi-asserted-by":"publisher","first-page":"R189","DOI":"10.1530\/EJE-15-1028","volume":"174","author":"B Mayr","year":"2016","unstructured":"Mayr B, Schnabel D, Do Rr HGN, Sch\u00f6fl C (2016) GENETICS IN ENDOCRINOLOGY: Gain and loss of function mutations of the calcium-sensing receptor and associated proteins: current treatment concepts. Eur J Endocrinol 174:R189\u2013R208. https:\/\/doi.org\/10.1530\/EJE-15-1028","journal-title":"Eur J Endocrinol"},{"key":"2496_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/APA.12743","volume":"103","author":"SB Thim","year":"2014","unstructured":"Thim SB, Birkeb\u00e6k NH, Nissen PH, H\u00f8st C (2014) Activating calcium-sensing receptor gene variants in children: a case study of infant hypocalcaemia and literature review. Acta Paediatr 103:1117\u20131125. https:\/\/doi.org\/10.1111\/APA.12743","journal-title":"Acta Paediatr"},{"key":"2496_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/humu.20067","volume":"24","author":"S Pidasheva","year":"2004","unstructured":"Pidasheva S, D\u2019Souza-Li L, Canaff L et al (2004) CASRdb: calcium-sensing receptor locus-specific database for mutations causing familial (benign) hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum Mutat 24:107\u2013111. https:\/\/doi.org\/10.1002\/humu.20067","journal-title":"Hum Mutat"},{"key":"2496_CR22","doi-asserted-by":"publisher","unstructured":"Festas Silva D, De Sousa Lages A, Caetano JS et al (2021) A variant in the CASR gene (c.368T\u2009>\u2009C) causing hypocalcemia refractory to standard medical therapy. Endocrinol Diabetes Metab Case Rep 2021:. https:\/\/doi.org\/10.1530\/EDM-21-0005","DOI":"10.1530\/EDM-21-0005"},{"key":"2496_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1530\/EJE-18-0580","volume":"180","author":"K David","year":"2019","unstructured":"David K, Moyson C, Vanderschueren D, Decallonne B (2019) Long-term complications in patients with chronic hypoparathyroidism: a cross-sectional study. Eur J Endocrinol 180:71\u201378. https:\/\/doi.org\/10.1530\/EJE-18-0580","journal-title":"Eur J Endocrinol"},{"key":"2496_CR24","doi-asserted-by":"publisher","unstructured":"Mazoni L, Matrone \u00b7 A, Apicella \u00b7 M et al (2022) Renal complications and quality of life in postsurgical hypoparathyroidism: a case-control study. 45:573\u2013582. https:\/\/doi.org\/10.1007\/s40618-021-01686-2","DOI":"10.1007\/s40618-021-01686-2"},{"key":"2496_CR25","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s40618-022-01822-6","volume":"45","author":"F Saponaro","year":"2022","unstructured":"Saponaro F, Alfi \u00b7 G, Cetani \u00b7 F et al (2022) Serum calcium levels are associated with cognitive function in hypoparathyroidism: a neuropsychological and biochemical study in an Italian cohort of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Invest 45:1909\u20131918. https:\/\/doi.org\/10.1007\/s40618-022-01822-6","journal-title":"J Endocrinol Invest"},{"key":"2496_CR26","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1210\/CLINEM\/DGAB162","volume":"106","author":"G Zavatta","year":"2021","unstructured":"Zavatta G, Tebben PJ, McCollough CH et al (2021) Basal ganglia calcification is Associated with Local and systemic metabolic mechanisms in adult hypoparathyroidism. J Clin Endocrinol Metab 106:1900\u20131917. https:\/\/doi.org\/10.1210\/CLINEM\/DGAB162","journal-title":"J Clin Endocrinol Metab"},{"key":"2496_CR27","doi-asserted-by":"publisher","unstructured":"Elston MS, Elajnaf T, Hannan FM, Thakker RV (2022) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Associated with Myoclonus and Intracerebral calcifications. J Endocr Soc 6. https:\/\/doi.org\/10.1210\/JENDSO\/BVAC042","DOI":"10.1210\/JENDSO\/BVAC042"},{"key":"2496_CR28","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1530\/EJE-12-0946","volume":"168","author":"S Aggarwal","year":"2013","unstructured":"Aggarwal S, Kailash S, Sagar R et al (2013) Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium. Eur J Endocrinol 168:895\u2013903. https:\/\/doi.org\/10.1530\/EJE-12-0946","journal-title":"Eur J Endocrinol"},{"key":"2496_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.5144\/0256-4947.2013.411","volume":"33","author":"N Kamarthi","year":"2013","unstructured":"Kamarthi N, Venkatraman S, Patil PB (2013) Dental findings in the diagnosis of idiopathic hypoparathyroidism. Ann Saudi Med 33:411\u2013413. https:\/\/doi.org\/10.5144\/0256-4947.2013.411","journal-title":"Ann Saudi Med"},{"key":"2496_CR30","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/J.YMGME.2012.06.012","volume":"107","author":"V Guarnieri","year":"2012","unstructured":"Guarnieri V, Valentina D\u2019Elia A, Baorda F et al (2012) CASR gene activating mutations in two families with autosomal dominant hypocalcemia. Mol Genet Metab 107:548\u2013552. https:\/\/doi.org\/10.1016\/J.YMGME.2012.06.012","journal-title":"Mol Genet Metab"},{"key":"2496_CR31","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1530\/JME-16-0124","volume":"57","author":"FM Hannan","year":"2016","unstructured":"Hannan FM, Babinsky VN, Thakker RV (2016) Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis. J Mol Endocrinol 57:R127\u2013R142. https:\/\/doi.org\/10.1530\/JME-16-0124","journal-title":"J Mol Endocrinol"},{"key":"2496_CR32","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1210\/jc.2015-3910","volume":"101","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian JP, Brandi ML, Cusano NE et al (2016) Management of Hypoparathyroidism: Present and Future Physiology, Pathophysiology, and Nutritional aspects of Hypoparathyroidism. J Clin Endocrinol Metab 101:2313\u20132324. https:\/\/doi.org\/10.1210\/jc.2015-3910","journal-title":"J Clin Endocrinol Metab"},{"key":"2496_CR33","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1210\/JC.2015-3907","volume":"101","author":"ML Brandi","year":"2016","unstructured":"Brandi ML, Bilezikian JP, Shoback D et al (2016) Management of Hypoparathyroidism: Summary Statement and Guidelines. J Clin Endocrinol Metab 101:2273\u20132283. https:\/\/doi.org\/10.1210\/JC.2015-3907","journal-title":"J Clin Endocrinol Metab"},{"key":"2496_CR34","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-15-0628","volume":"173","author":"J Bollerslev","year":"2015","unstructured":"Bollerslev J, Rejnmark L, Marcocci C et al (2015) European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 173:G1\u2013G20. https:\/\/doi.org\/10.1530\/EJE-15-0628","journal-title":"Eur J Endocrinol"},{"key":"2496_CR35","doi-asserted-by":"publisher","first-page":"651","DOI":"10.20945\/2359-3997000000554","volume":"66","author":"EN Sakane","year":"2022","unstructured":"Sakane EN, Vieira MCC, Vieira GMM, Maeda SS (2022) Treatment options in hypoparathyroidism. Arch Endocrinol Metab 66:651\u2013657. https:\/\/doi.org\/10.20945\/2359-3997000000554","journal-title":"Arch Endocrinol Metab"},{"key":"2496_CR36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/AJCN\/41.2.254","volume":"41","author":"RR Recker","year":"1985","unstructured":"Recker RR, Heaney RP (1985) The effect of milk supplements on calcium metabolism, bone metabolism and calcium balance. Am J Clin Nutr 41:254\u2013263. https:\/\/doi.org\/10.1093\/AJCN\/41.2.254","journal-title":"Am J Clin Nutr"},{"key":"2496_CR37","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/0115426507022003286","volume":"22","author":"DA Straub","year":"2007","unstructured":"Straub DA (2007) Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract 22:286\u2013296. https:\/\/doi.org\/10.1177\/0115426507022003286","journal-title":"Nutr Clin Pract"},{"key":"2496_CR38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.20945\/2359-3997000000015","volume":"62","author":"SS Maeda","year":"2018","unstructured":"Maeda SS, Moreira CA, Borba VZC et al (2018) Diagnosis and treatment of hypoparathyroidism: a position statement from the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab 62:106\u2013124. https:\/\/doi.org\/10.20945\/2359-3997000000015","journal-title":"Arch Endocrinol Metab"},{"key":"2496_CR39","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1210\/CLINEM\/DGAA113","volume":"105","author":"JP Bilezikia","year":"2020","unstructured":"Bilezikia JP (2020) Hypoparathyroidism. J Clin Endocrinol Metab 105:1722. https:\/\/doi.org\/10.1210\/CLINEM\/DGAA113","journal-title":"J Clin Endocrinol Metab"},{"key":"2496_CR40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/S10157-015-1160-9","volume":"20","author":"N Kamiyoshi","year":"2016","unstructured":"Kamiyoshi N, Nozu K, Urahama Y et al (2016) Pathogenesis of hypokalemia in autosomal dominant hypocalcemia type 1. Clin Exp Nephrol 20:253\u2013257. https:\/\/doi.org\/10.1007\/S10157-015-1160-9","journal-title":"Clin Exp Nephrol"},{"key":"2496_CR41","doi-asserted-by":"publisher","unstructured":"Vahe C, Benomar K, Espiard S et al (2017) Diseases associated with calcium-sensing receptor. Orphanet J Rare Dis 12. https:\/\/doi.org\/10.1186\/S13023-017-0570-Z","DOI":"10.1186\/S13023-017-0570-Z"},{"key":"2496_CR42","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/J.ECL.2018.07.009","volume":"47","author":"M Peacock","year":"2018","unstructured":"Peacock M (2018) Hypoparathyroidism and the kidney. Endocrinol Metab Clin North Am 47:839\u2013853. https:\/\/doi.org\/10.1016\/J.ECL.2018.07.009","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2496_CR43","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMCP1800213","volume":"380","author":"RI Gafni","year":"2019","unstructured":"Gafni RI, Collins MT (2019) Hypoparathyroidism. N Engl J Med 380:1738\u20131747. https:\/\/doi.org\/10.1056\/NEJMCP1800213","journal-title":"N Engl J Med"},{"key":"2496_CR44","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jama.276.8.631","volume":"276","author":"KK Winer","year":"1996","unstructured":"Winer KK, Yanovski JA, Cutler GB (1996) Synthetic human parathyroid hormone 1\u201334 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 276:631\u2013636. https:\/\/doi.org\/10.1001\/jama.276.8.631","journal-title":"JAMA"},{"key":"2496_CR45","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1210\/JC.83.10.3480","volume":"83","author":"KK Winer","year":"1998","unstructured":"Winer KK, Yanovski JA, Sarani B, Cutler GB (1998) A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1\u201334 in treatment of hypoparathyroidism. J Clin Endocrinol Metab 83:3480\u20133486. https:\/\/doi.org\/10.1210\/JC.83.10.3480","journal-title":"J Clin Endocrinol Metab"},{"key":"2496_CR46","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1210\/JC.2007-2552","volume":"93","author":"KK Winer","year":"2008","unstructured":"Winer KK, Sinaii N, Peterson D et al (2008) Effects of once versus twice-daily parathyroid hormone 1\u201334 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab 93:3389\u20133395. https:\/\/doi.org\/10.1210\/JC.2007-2552","journal-title":"J Clin Endocrinol Metab"},{"key":"2496_CR47","doi-asserted-by":"publisher","unstructured":"Winer KK, Fulton KA, Albert PS, Cutler GB (2014) Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1\u201334 in children with severe congenital hypoparathyroidism. J Pediatr 165. https:\/\/doi.org\/10.1016\/J.JPEDS.2014.04.060","DOI":"10.1016\/J.JPEDS.2014.04.060"},{"key":"2496_CR48","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1056\/NEJMC2034981","volume":"385","author":"A Sastre","year":"2021","unstructured":"Sastre A, Valentino K, Hannan FM et al (2021) PTH infusion for seizures in autosomal Dominant Hypocalcemia Type 1. N Engl J Med 385:189\u2013191. https:\/\/doi.org\/10.1056\/NEJMC2034981","journal-title":"N Engl J Med"},{"key":"2496_CR49","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","volume":"1","author":"M Mannstadt","year":"2013","unstructured":"Mannstadt M, Clarke BL, Vokes T et al (2013) Efficacy and safety of recombinant human parathyroid hormone (1\u201384) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol 1:275\u2013283. https:\/\/doi.org\/10.1016\/S2213-8587(13)70106-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2496_CR50","doi-asserted-by":"publisher","first-page":"K13","DOI":"10.1530\/EJE-20-0710","volume":"183","author":"CP Hawkes","year":"2020","unstructured":"Hawkes CP, Shulman DI, Levine MA (2020) Recombinant human parathyroid hormone (1\u201384) is effective in CASR-associated hypoparathyroidism. Eur J Endocrinol 183:K13\u2013K21. https:\/\/doi.org\/10.1530\/EJE-20-0710","journal-title":"Eur J Endocrinol"},{"key":"2496_CR51","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1002\/JBMR.3824","volume":"34","author":"L Holten-Andersen","year":"2019","unstructured":"Holten-Andersen L, Pihl S, Rasmussen CE et al (2019) Design and Preclinical Development of TransCon PTH, an Investigational sustained-release PTH replacement therapy for Hypoparathyroidism. J Bone Min Res 34:2075\u20132086. https:\/\/doi.org\/10.1002\/JBMR.3824","journal-title":"J Bone Min Res"},{"key":"2496_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/JBMR.4726","author":"AA Khan","year":"2022","unstructured":"Khan AA, Rubin MR, Schwarz P et al (2022) Efficacy and safety of parathyroid hormone replacement with TransCon PTH in Hypoparathyroidism: 26-Week results from the phase 3 PaTHway Trial. J Bone Min Res. https:\/\/doi.org\/10.1002\/JBMR.4726","journal-title":"J Bone Min Res"},{"key":"2496_CR53","doi-asserted-by":"publisher","first-page":"A254","DOI":"10.1210\/JENDSO\/BVAB048.516","volume":"5","author":"S Allas","year":"2021","unstructured":"Allas S, Ovize M, Culler MD et al (2021) A single administration of AZP-3601, a Novel, Long-acting PTH Analog, induces a significant and sustained calcemic response: Preliminary Data from a Randomized, Double-Blind, placebo-controlled phase 1 study. J Endocr Soc 5:A254. https:\/\/doi.org\/10.1210\/JENDSO\/BVAB048.516","journal-title":"J Endocr Soc"},{"key":"2496_CR54","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/JBMR.2811","volume":"31","author":"M Shimizu","year":"2016","unstructured":"Shimizu M, Joyashiki E, Noda H et al (2016) Pharmacodynamic actions of a long-acting PTH Analog (LA-PTH) in Thyroparathyroidectomized (TPTX) rats and normal monkeys. J Bone Min Res 31:1405\u20131412. https:\/\/doi.org\/10.1002\/JBMR.2811","journal-title":"J Bone Min Res"},{"key":"2496_CR55","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/BPH.14028","volume":"175","author":"V Krishnan","year":"2018","unstructured":"Krishnan V, Ma YL, Chen CZ et al (2018) Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism. Br J Pharmacol 175:262\u2013271. https:\/\/doi.org\/10.1111\/BPH.14028","journal-title":"Br J Pharmacol"},{"key":"2496_CR56","doi-asserted-by":"publisher","unstructured":"Tamura T, Noda H, Joyashiki E et al (2016) Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism. Nat Commun 7. https:\/\/doi.org\/10.1038\/NCOMMS13384","DOI":"10.1038\/NCOMMS13384"},{"key":"2496_CR57","unstructured":"Study Record| Beta ClinicalTrials.gov. https:\/\/beta.clinicaltrials.gov\/study\/NCT04209179. Accessed 28 Nov 2022"},{"key":"2496_CR58","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/JBMR.4274","volume":"36","author":"S Ish-Shalom","year":"2021","unstructured":"Ish-Shalom S, Caraco Y, Khazen NS et al (2021) Safety and efficacy of oral human parathyroid hormone (1\u201334) in hypoparathyroidism: an open-label study. J Bone Min Res 36:1060\u20131068. https:\/\/doi.org\/10.1002\/JBMR.4274","journal-title":"J Bone Min Res"},{"key":"2496_CR59","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/J.BEEM.2013.02.008","volume":"27","author":"EF Nemeth","year":"2013","unstructured":"Nemeth EF, Shoback D (2013) Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders. Best Pract Res Clin Endocrinol Metab 27:373\u2013384. https:\/\/doi.org\/10.1016\/J.BEEM.2013.02.008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2496_CR60","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/J.TEM.2016.05.005","volume":"27","author":"B Mayr","year":"2016","unstructured":"Mayr B, Glaudo M, Sch\u00f6fl C (2016) Activating calcium-sensing receptor mutations: prospects for future treatment with Calcilytics. Trends Endocrinol Metab 27:643\u2013652. https:\/\/doi.org\/10.1016\/J.TEM.2016.05.005","journal-title":"Trends Endocrinol Metab"},{"key":"2496_CR61","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/NRNEPH.2016.59","volume":"12","author":"D Riccardi","year":"2016","unstructured":"Riccardi D, Valenti G (2016) Localization and function of the renal calcium-sensing receptor. Nat Rev Nephrol 12:414\u2013425. https:\/\/doi.org\/10.1038\/NRNEPH.2016.59","journal-title":"Nat Rev Nephrol"},{"key":"2496_CR62","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1002\/JBMR.2551","volume":"30","author":"B Dong","year":"2015","unstructured":"Dong B, Endo I, Ohnishi Y et al (2015) Calcilytic ameliorates abnormalities of mutant calcium-sensing receptor (CaSR) Knock-In mice mimicking autosomal Dominant Hypocalcemia (ADH). J Bone Min Res 30:1980\u20131993. https:\/\/doi.org\/10.1002\/JBMR.2551","journal-title":"J Bone Min Res"},{"key":"2496_CR63","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1210\/EN.2015-1269","volume":"156","author":"FM Hannan","year":"2015","unstructured":"Hannan FM, Walls GV, Babinsky VN et al (2015) The Calcilytic Agent NPS 2143 rectifies Hypocalcemia in a mouse Model with an activating calcium-sensing receptor (CaSR) mutation: relevance to autosomal Dominant Hypocalcemia Type 1 (ADH1). Endocrinology 156:3114\u20133121. https:\/\/doi.org\/10.1210\/EN.2015-1269","journal-title":"Endocrinology"},{"key":"2496_CR64","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1002\/JBMR.3747","volume":"34","author":"MS Roberts","year":"2019","unstructured":"Roberts MS, Gafni RI, Brillante B et al (2019) Treatment of autosomal Dominant Hypocalcemia Type 1 with the calcilytic NPSP795 (SHP635). J Bone Min Res 34:1609\u20131618. https:\/\/doi.org\/10.1002\/JBMR.3747","journal-title":"J Bone Min Res"},{"key":"2496_CR65","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1056\/NEJMC2302708","volume":"389","author":"RI Gafni","year":"2023","unstructured":"Gafni RI, Hartley IR, Roszko KL et al (2023) Efficacy and safety of Encaleret in autosomal Dominant Hypocalcemia Type 1. N Engl J Med 389:1245\u20131247. https:\/\/doi.org\/10.1056\/NEJMC2302708","journal-title":"N Engl J Med"},{"key":"2496_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/JBMR.4698","author":"S Van Uum","year":"2022","unstructured":"Van Uum S, Shrayyef M, M\u2019Hiri I et al (2022) Initial Assessment and Monitoring of patients with chronic hypoparathyroidism: a systematic current practice survey. J Bone Min Res. https:\/\/doi.org\/10.1002\/JBMR.4698","journal-title":"J Bone Min Res"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02496-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02496-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02496-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T08:44:30Z","timestamp":1743324270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02496-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":66,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["2496"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02496-y","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"14 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}